US 2012/0070461 A1 · USE OF MYELOID CELL BIOMARKERS FOR THE DIAGNOSIS OF CANCER

Abstract

The present invention relates to the use of myeloid cell biomarkers for the differential diagnosis, prognosis, and monitoring of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to monitoring the effect of a treatment against renal cell carcinoma (RCC) or colorectal cancer (CRC), and establishing a prognosis of the outcome of the treatment of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to panels of cellular biomarkers for use in the above methods, in particular multicolor panels for measuring said biomarkers.

Claims24

Dependent claims

A method for diagnosing and/or prognosing cancer, comprising

determining the level of at least one myeloid-derived suppressor cell (MDSC) phenotype in an MDSC population in a biological sample obtained from a patient based on at least one MDSC phenotype marker,
wherein said marker is selected from the group consisting of CD15;
IL4Ra;
CD14;
CD11b:
HLA-DR;
CD33;
Lin;
FSC;
SSC;
and, optionally CD45;
CD18;
CD80;
CD83;
CD86;
HLA-I;
Live/Dead discriminator and
wherein an increase of the level of said MDSC phenotypes compared to a non-cancer patient sample is indicative for cancer and/or a prognostic indicator for a treatment of said cancer.

15 more elements

Dependencies are inferred from the claim text.

Use of myeloid cell biomarkers for the diagnosis of cancer

Life of this patent

Use of myeloid cell biomarkers for the diagnosis of cancer

Life of this patent

Abstract

Claims24